Paliperidone Palmitate
FDA-approved product (suspension, extended release, intramuscular), marketed as Erzofri, Invega Hafyera, Invega Sustenna and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Mental or behavioural disorder
- Psychosis
- Schizoaffective disorder
- Schizophrenia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antipsychotics
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA67.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Paliperidone Palmitate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Bioequivalence Study of PP3M in Patients With Schizophrenia
NCT07493551 · start 2024-10-09
Registered record
- Registry ID
- NCT07493551
- Conditions
- Schizophrenia
- Interventions
- Paliperidone Palmitate Injection (3M)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2024-10-09
- Completion
- 2026-12-31
- Enrolment
- 260
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionPaliperidone Palmitate Injection (3M)PhaseNot applicableRegistry statusRecruitingBioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia
NCT07268430 · start 2023-12-18
Registered record
- Registry ID
- NCT07268430
- Conditions
- Schizophrenia
- Interventions
- Paliperidone Palmitate Injection(PP1M); Paliperidone Palmitate Injection(PP1M)(Reference Group)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-12-18
- Completion
- 2024-12-25
- Enrolment
- 256
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionPaliperidone Palmitate Injection(PP1M); Paliperidone Palmitate Injection(PP1M)(Reference Group)PhaseNot applicableRegistry statusCompletedMultidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
NCT06060886 · start 2023-11-01
Registered record
- Registry ID
- NCT06060886
- Conditions
- Schizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders; Diabetes; NAFLD; Psychosis
- Interventions
- Aripiprazole; Paliperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2023-11-01
- Completion
- 2025-12-31
- Enrolment
- 244
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders +3 moreInterventionAripiprazole; PaliperidonePhasePhase 4Registry statusUnknownRisk of Breakthrough Symptoms With Long-Acting Injectable Medications
NCT05473741 · start 2023-01-11
Registered record
- Registry ID
- NCT05473741
- Conditions
- Schizophrenia; Schizophrenia Relapse
- Interventions
- Second Generation Long-Acting Injectable Antipsychotic Medications
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2023-01-11
- Completion
- 2025-10-27
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Schizophrenia RelapseInterventionSecond Generation Long-Acting Injectable Antipsychotic MedicationsPhaseNot recordedRegistry statusCompleted"Extended" (Alternate Day) Antipsychotic Dosing
NCT04478838 · start 2022-06-06
Registered record
- Registry ID
- NCT04478838
- Conditions
- Schizophrenia and Related Disorders; Drug Administration Schedule; Drug Therapy; Antipsychotic Agents
- Interventions
- Risperidone; Olanzapine; paliperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2022-06-06
- Completion
- 2028-09-30
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia and Related Disorders; Drug Administration Schedule; Drug Therapy; Antipsychotic AgentsInterventionRisperidone; Olanzapine; paliperidonePhasePhase 4Registry statusRecruitingRelative Bioavailability of LY03010 Compared to Listed Drug
NCT04922593 · start 2021-01-13
Registered record
- Registry ID
- NCT04922593
- Conditions
- Schizophrenia; Psychotic Disorders; Mood Disorders; Schizophrenia Spectrum; Mental Disorders; Antipsychotic Agents; Tranquilizing Agents; Central Nervous System Depressants; Physiological Effects of Drugs; Psychotropic Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010; paliperidone palmitate; INVEGA SUSTENNA
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2021-01-13
- Completion
- 2022-04-15
- Enrolment
- 281
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Psychotic Disorders; Mood Disorders; Schizophrenia Spectrum +8 moreInterventionLY03010; paliperidone palmitate; INVEGA SUSTENNAPhasePhase 1Registry statusCompletedA Study of Paliperidone Palmitate 6-Month Formulation
NCT04072575 · start 2019-09-19
Registered record
- Registry ID
- NCT04072575
- Conditions
- Schizophrenia
- Interventions
- PP6M injection Dose 1; PP6M injection Dose 2
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2019-09-19
- Completion
- 2022-05-03
- Enrolment
- 178
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionPP6M injection Dose 1; PP6M injection Dose 2PhasePhase 3Registry statusCompletedA Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
NCT03713658 · start 2018-10-18
Registered record
- Registry ID
- NCT03713658
- Conditions
- Schizophrenia
- Interventions
- Risperidone 3 mg; Paliperidone Palmitate 50 mg eq.; Paliperidone Palmitate 75 mg eq.; Paliperidone Palmitate 100 mg eq.; Paliperidone Palmitate 150 mg eq.; Paliperidone Palmitate 175 mg eq.; Paliperidone Palmitate 263 mg eq.; Paliperidone Palmitate 350 mg eq.; Paliperidone Palmitate 525 mg eq.
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2018-10-18
- Completion
- 2019-12-02
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionRisperidone 3 mg; Paliperidone Palmitate 50 mg eq.; Paliperidone Palmitate 75 mg eq.; Paliperidone Palmitate 100 mg eq. +5 morePhasePhase 4Registry statusCompletedA Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
NCT03666715 · start 2018-08-07
Registered record
- Registry ID
- NCT03666715
- Conditions
- Schizophrenia
- Interventions
- Oral Antipsychotics (OAPs); Paliperidone Palmitate 1-Month Formulation (PP1M)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2018-08-07
- Completion
- 2021-05-31
- Enrolment
- 55
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionOral Antipsychotics (OAPs); Paliperidone Palmitate 1-Month Formulation (PP1M)PhaseNot recordedRegistry statusCompletedA Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
NCT03557931 · start 2018-07-13
Registered record
- Registry ID
- NCT03557931
- Conditions
- Schizophrenia
- Interventions
- ASP4345; placebo; risperidone; quetiapine; olanzapine; ziprasidone; aripiprazole; brexpiprazole; paliperidone; lurasidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2018-07-13
- Completion
- 2019-10-21
- Enrolment
- 233
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionASP4345; placebo; risperidone; quetiapine +6 morePhasePhase 2Registry statusCompletedThe Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia
NCT03434210 · start 2018-05-05
Registered record
- Registry ID
- NCT03434210
- Conditions
- Schizophrenia
- Interventions
- LAT-treated Community Model; care as usual
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2018-05-05
- Completion
- 2020-10
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionLAT-treated Community Model; care as usualPhaseNot applicableRegistry statusUnknownA Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
NCT03425552 · start 2018-03-11
Registered record
- Registry ID
- NCT03425552
- Conditions
- Schizophrenia
- Interventions
- Paliperidone; Paliperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2018-03-11
- Completion
- 2019-05-02
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionPaliperidone; PaliperidonePhasePhase 1 / Phase 2Registry statusCompletedA Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
NCT02713282 · start 2016-04-28
Registered record
- Registry ID
- NCT02713282
- Conditions
- Schizophrenia
- Interventions
- Paliperidone palmitate 3 month formulation (PP3M)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-04-28
- Completion
- 2018-03-26
- Enrolment
- 306
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionPaliperidone palmitate 3 month formulation (PP3M)PhasePhase 3Registry statusCompletedNon-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate
NCT02532842 · start 2015-07
Registered record
- Registry ID
- NCT02532842
- Conditions
- Schizophrenia
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-07
- Completion
- 2015-09
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionNot recordedPhaseNot recordedRegistry statusCompletedA Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
NCT02462473 · start 2015-05
Registered record
- Registry ID
- NCT02462473
- Conditions
- Schizophrenia; Schizoaffective Disorder
- Interventions
- Aripiprazole; Olanzapine; Paliperidone; Quetiapine; Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2015-05
- Completion
- 2016-01
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Schizoaffective DisorderInterventionAripiprazole; Olanzapine; Paliperidone; Quetiapine +1 morePhasePhase 2Registry statusTerminated